Mendelian randomization for cardiovascular diseases: principles and applications
SC Larsson, AS Butterworth… - European heart journal, 2023 - academic.oup.com
Large-scale genome-wide association studies conducted over the last decade have
uncovered numerous genetic variants associated with cardiometabolic traits and risk factors …
uncovered numerous genetic variants associated with cardiometabolic traits and risk factors …
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of …
F Mach, C Baigent, AL Catapano… - European heart …, 2020 - academic.oup.com
version of the Guidelines, which is freely available via the ESC and EAS websites and
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …
hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac …
The MR-Base platform supports systematic causal inference across the human phenome
Results from genome-wide association studies (GWAS) can be used to infer causal
relationships between phenotypes, using a strategy known as 2-sample Mendelian …
relationships between phenotypes, using a strategy known as 2-sample Mendelian …
Recent developments in Mendelian randomization studies
Abstract Purpose of Review Mendelian randomization (MR) is a strategy for evaluating
causality in observational epidemiological studies. MR exploits the fact that genotypes are …
causality in observational epidemiological studies. MR exploits the fact that genotypes are …
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new …
Background The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab
reduced LDL cholesterol and cardiovascular events in the FOURIER trial. In this …
reduced LDL cholesterol and cardiovascular events in the FOURIER trial. In this …
Safety and efficacy of statin therapy
BB Adhyaru, TA Jacobson - Nature Reviews Cardiology, 2018 - nature.com
The 2013 ACC/AHA guidelines on blood cholesterol management were a major shift in the
delineation of the main patient groups that could benefit from statin therapy and emphasized …
delineation of the main patient groups that could benefit from statin therapy and emphasized …
Cardiovascular efficacy and safety of bococizumab in high-risk patients
PM Ridker, J Revkin, P Amarenco… - … England Journal of …, 2017 - Mass Medical Soc
Background Bococizumab is a humanized monoclonal antibody that inhibits proprotein
convertase subtilisin–kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein …
convertase subtilisin–kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein …
Mendelian randomization in cardiometabolic disease: challenges in evaluating causality
Mendelian randomization (MR) is a burgeoning field that involves the use of genetic variants
to assess causal relationships between exposures and outcomes. MR studies can be …
to assess causal relationships between exposures and outcomes. MR studies can be …
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the …
Background After acute coronary syndrome, diabetes conveys an excess risk of ischaemic
cardiovascular events. A reduction in mean LDL cholesterol to 1· 4–1· 8 mmol/L with …
cardiovascular events. A reduction in mean LDL cholesterol to 1· 4–1· 8 mmol/L with …
Adverse effects of statin therapy: perception vs. the evidence–focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract
F Mach, KK Ray, O Wiklund, A Corsini… - European heart …, 2018 - academic.oup.com
Aims To objectively appraise evidence for possible adverse effects of long-term statin
therapy on glucose homeostasis, cognitive, renal and hepatic function, and risk for …
therapy on glucose homeostasis, cognitive, renal and hepatic function, and risk for …